Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
References (25)
- et al.
Structure-activity studies of GLP-1
J. Biol. Chem.
(1994) - et al.
Effect of GLP-1 on hepatic glucose production in healthy man
Metabolism
(1994) - et al.
Amino acid sequence and heterogeneity of gastric inhibitory polypeptide
FEBS Lett.
(1981) - et al.
Comparison of sandwich ELISA and RIA for detection of exogenous GLP-1-(7–36) amide in plasma
J. Pharm. Biomed. Anal.
(1995) - et al.
Enzymatic iodination of polypeptide with (125I) to high specific activity
Biochim. Biophys. Acta
(1971) - et al.
Insulinotropic effect of GLP-1-(7–37) in non-insulin dependent diabetes mellitus patients: a study of dose and glucose dependency
Clin. Res.
(1992) - et al.
Degradation of GLP-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
J. Clin. Endocrinol. Metab.
(1995) - et al.
Both subcutaneous and intravenously administered GLP-1 are rapidly degraded from the N-terminus in type-2 diabetic patients and in healthy subjects
Diabetes
(1995) - et al.
Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells
Diabetes
(1991) - et al.
GLP-1-(7–36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretionresponse to nutrient ingestion in man: Acute post-prandial and 24-h secretion pattern
J. Endocrinol.
(1993)
Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma
J. Clin. Invest.
(1989)
Structure-activity characterization of glucagon-like peptide-1
Eur. J. Biochem.
(1994)
Cited by (216)
Peptides in the regulation of glucagon secretion
2022, PeptidesDesign and synthesis of chemically modified peptides and proteins —critical considerations for oral delivery
2022, Oral Delivery of Therapeutic Peptides and ProteinsEffects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus
2022, Vitamins and HormonesSynthetic protease-activated class B GPCRs
2020, Biochemical and Biophysical Research CommunicationsCitation Excerpt :In vivo, GLP-1(7–36) is inactivated by the protease DPP4 which cleaves the His7-Ala8 dipeptide from the amino terminus [28]. GLP-1(9–36) is the inactive metabolite that is characterized in various systems as an antagonist, low efficacy partial agonist or inactive [29]. Addition of enterokinase to INS-1 cells expressing the GLP-1R-GLP-1(9–36) chimera did not elevate intracellular cAMP (Fig. 3A).
Copyright © 1996 Published by Elsevier B.V.